Enforcement Report - Week of April 24, 2024
CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe
FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET®
Esperion & Daiichi Sankyo Announce $125 Million Amendment to Their Collaboration
After a dispute over milestone payments derailed a 2019 heart med collaboration, Daiichi Sankyo and Esperion Therapeutics have mended fences with a $125 million settlement.
Enforcement Report - Week of September 13, 2023
Esperion Therapeutics is ending an R&D collaboration with Serometrix centered on the former's oral PCSK candidate, two and a half years after paying $12.5 million to partner up.
After Esperion Therapeutics disclosed a conflict with Nexletol partner Daiichi Sankyo in an SEC filing earlier this month, the company has kicked it up a notch with a lawsuit claiming it's entitled to $300 million in milestone payments.
Shares of Esperion Therapeutics lost more than half their value Thursday morning on fears the company may not get a $300 million milestone payment from Daiichi Sankyo.
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Session